We used cross-sectional analyses to estimate prevalence of DBMD per 10 000 boys, ages 5 to 9 years, for 4 quinquennia (1991-1995, 1996-2000, 2001-2005, and 2006-2010) and prevalence per 10 000 male individuals, ages 5 to 24 years, in 2010. Prevalence was also estimated by race/ethnicity and phenotype.
WHAT'S KNOWN ON THIS SUBJECT:
Worldwide prevalence estimates of Duchenne and Becker muscular dystrophies (DBMD) vary, likely due to differences in diagnostic criteria, ascertainment, and survival. To date, no population-based prevalence data for DBMD by race/ethnicity have been published in the United States.
WHAT THIS STUDY ADDS:
Approximately 2 per 10 000 boys, ages 5 to 9 years, in 6 sites in the United States have DBMD; prevalence remained rather constant across 4 birth cohorts that spanned 2 decades. Prevalence differed among selected racial/ethnic groups across the time period examined.
Duchenne and Becker muscular dystrophies (DBMD) are allelic X-linked neuromuscular disorders. Worldwide, prevalence of DBMD has ranged from 0.1 to 1.8 per 10 000 male individuals. [1] [2] [3] [4] [5] [6] [7] Studies of Duchenne muscular dystrophy (DMD) prevalence (per 10 000 male individuals) suggest estimates of 0.1 in South Africa, 1 0.5 to 1.0 in Asian countries, 2, 3, 8, 9 0.7 to 1.0 in North America, 5, 10 and 0.2 to 2.8 in European countries. 4, 6, 7, [11] [12] [13] [14] [15] [16] [17] [18] [19] Some of these studies also examined Becker muscular dystrophy (BMD) prevalence, suggesting corresponding estimates of 0.01, 1 0.1 to 0.2, 2,3 0.2, 5 and 0.1 to 0.7, 4, 6, 7 respectively. A recent meta-analysis of worldwide prevalence of muscular dystrophies suggests prevalences of DMD and BMD as 0.5 and 0.1 per 10 000 male individuals, respectively. 20 Differences in prevalence may reflect changes in diagnostic methods, along with racial/ethnic variations and age ranges of the populations studied.
Current clinical management, such as steroid use, 21 ventilatory assistance, [22] [23] [24] and scoliosis surgery, 25 has improved survival for patients with DBMD. This improved survival is accompanied by new multisystem complications and the need for long-term care. 26 Appropriate management is predicted to improve quality of life for patients and their families. For example, families with an affected child require more support/social services to help cope with caring for the child and the concomitant increase in health care costs. 27, 28 Improved understanding of overall and age-specific prevalence of DBMD is critical to help plan for medical and social services, particularly as children transition from pediatric to adult services, and to evaluate the impact of lifeprolonging therapies. 29 ; before our report, the most recent US prevalence estimates were published in 1974. 30 In our current report, we present data from all MD STARnet sites through 2010 and estimate population-based prevalence for DBMD by age, race/ ethnicity, and phenotype.
METHODS
The MD STARnet is a US, multisite population-based cohort for surveillance and research of DBMD. 31 Sites comprise Arizona, Colorado, Georgia, Hawaii, Iowa, and the western 12 counties of New York State (henceforth termed New York). Public health authority for birth defects surveillance in Colorado, Georgia, Iowa, and New York was expanded to permit active case finding and record abstraction for DBMD; in Arizona and Hawaii, institutional review board approval was obtained for these activities from the University of Arizona and the Hawaii Department of Health, respectively, and as needed, health care facilities where data collection occurred.
Surveillance Data Collection
An eligible MD STARnet case had a birthdate on or after January 1, 1982, and on or before December 31, 2011, resided in an MD STARnet site during any part of that time period, and was diagnosed with childhoodonset DBMD. As described elsewhere, 31 Table 4 ). 32 If the individual reviews were concordant, the case was assigned to the consensus definition; if discordant, they were discussed by all physicians to generate a consensus definition. Case race/ethnicity was assigned as recorded in medical record data, or if missing, birth parent data from birth certificates or medical records. If recorded maternal and paternal race/ ethnicity matched (eg, both listed as Hispanic), the case was imputed by that value; if it differed (eg, one listed as Hispanic, the other as non-Hispanic white), the case was assigned as multiple race/ethnicity. If only maternal race/ethnicity was available, the case was assigned that value; missing maternal data generated missing case race/ ethnicity.
Residence at diagnosis and at each subsequent identified clinic visit was used to systematically assign case annual residence from birth year through December 31, 2010. Cases who remained in an MD STARnet site from the previous calendar year or who moved into the site, died, or migrated out during a calendar year were assigned residence in that site for that year. Cases that relocated from one site to another were assigned residence in the most recent site the year after migration to maintain independent observations per year. Cases with 2 or more years between identified clinic visits in a site were assigned residence in that site for those years; those without an identified clinic visit for 3 or more years after their most recent identified clinic visit were censored in the year of their most recent identified visit.
Phenotype was assigned based on age of first symptoms. If the earliest MD symptoms reportedly occurred before the fifth birthday, the case was assigned as DMD. If symptoms occurred on or after the fifth birthday, the case was assigned as BMD. 34 
Survey Data Collection
Beginning in 2007, primary caregivers (in priority order: birth mother, birth father, legal guardian) of definite and probable cases were invited to participate in a telephone survey to supplement data (eg, socioeconomic factors, social support) collected by medical record abstraction. 35 We conducted 3 sensitivity analyses. We compared residence histories generated from surveillance data with self-reports from the telephone surveys to evaluate the use of available medical records to generate residence histories. We also estimated prevalence including possible and asymptomatic cases to examine potential bias introduced by variability in the quality and availability of clinical data among sites. Last, we estimated prevalence restricting the sample to the oldest case in each family to discern the impact that families with more than 1 case contributed to prevalence. Tables 5  and 6 ); the larger increase in the earlier quinquennia reflected the higher number of possible and asymptomatic cases in those years. Also, racial/ethnic-specific estimates that included possible and asymptomatic cases were slightly increased compared with those for definite and probable cases (Supplemental Tables 5 and 6 ).
RESULTS

Overall
Restriction of cases to the oldest case in each family attenuated the estimates, but preserved patterns identified for pooled prevalence (data not shown).
DISCUSSION
We present population-based estimates of the prevalence of childhood-onset DBMD in 6 US sites. Prevalence among 5-to 9-year-olds was approximately 2 per 10 000 boys, in all quinquennia except 2006-2010. Prevalence among non-Hispanic white individuals paralleled that for all racial/ethnic groups combined, whereas prevalence among Hispanic individuals decreased across quinquennia, but tended to exceed that for other racial/ethnic groups examined; prevalence was lowest among non-Hispanic black individuals. Also, DMD was 3 times more prevalent than BMD. In 2010, prevalence of DBMD among 5-to 24-year-olds was 1.38 per 10 000 male individuals.
The lower prevalence in 2006-2010 may reflect delayed diagnosis of DBMD among MD STARnet cases. 33 It also may reflect a change in parental reproductive choice; however, a separate analysis observed that reproductive patterns of MD STARnet mothers after knowledge of family history of DBMD tended to be similar to those without such family history. 36 The similar estimates for all cases and non-Hispanic white cases reflect the sizable proportion of non-Hispanic white individuals in the MD STARnet; future efforts will include expanding surveillance among minority populations. It also may reflect racial/ethnic differences in time to diagnosis and access to care, random fluctuations, or true differences in prevalence of DBMD across these racial/ethnic groups. Conversely, the increased prevalence among Hispanic individuals may reflect suspected underreporting in census estimates for Hispanic children, ages 5 to 9 years. 37 Additionally, our definitions for DMD and BMD, determined from age of onset of signs and symptoms, may have also biased the true prevalence of each phenotype.
Previous data are unavailable to compare prevalence of DBMD for consecutive cohorts of boys, ages 5 to 9 years. Our prevalence of 1.38 per 10 000 male individuals, ages 5 to 24 years was lower than the 1.8 per 10 000 boys younger than 16 years in western Sweden. 7 It also was less comparable to other studies of original data, which reported prevalence of DBMD among all male individuals in the population. By using 2010 US census data, which showed that 29.0% of all male individuals in the MD STARnet sites were ages 5 to 24 years, 38 In our subgroup analyses, prevalence patterns observed for non-Hispanic white and black individuals were similar to those reported in South Africa, being higher in white and lower in black individuals. 1 Our prevalence of 1.12 for DMD among male individuals, ages 5 to 24 years, in 2010 was lower than the prevalence (2.8) for male individuals, ages 20 years or younger, in Bologna, Italy, 18 and that (2.4) for boys, ages 5 to 16 years, in Birmingham, United Kingdom. 19 Again, extrapolating our DMD prevalence estimate to all male individuals (0.3 per 10 000) was comparable to DMD prevalence in several other countries (0.2-0.8). [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Similarly, extrapolating our BMD prevalence estimate to all male individuals (0.1 per 10 000) was comparable to several other studies (0.1-0.2), [2] [3] [4] [5] 7 although it was higher than the prevalence (0.01) in South Africa 1 and lower than that (0.7) in northern England. 6 Additional DMD or BMD studies were less comparable to ours, as they provided estimates per total residents rather than those for male individuals only, or reported
FIGURE 1
Prevalence estimates per 10 000 male individuals by quinquennium with and without possible and asymptomatic cases, identified by MD STARnet, 1991-2010.
FIGURE 2
Prevalence estimates for 2010 per 10 000 male individuals by age group, with and without possible and asymptomatic cases, identified by MD STARnet, 1991-2010.
estimates among live male births. [39] [40] [41] [42] [43] [44] [45] [46] [47] Prevalence differences identified between our study and previous studies may reflect the changes in diagnostic methods over the past quarter century; many studies 5, [8] [9] [10] 12, 16, 19 predated current diagnostic methods, potentially leading to misclassification of muscular dystrophy type. Prevalence differences identified may also be due, in part, to the racial/ethnic composition of our sample; specifically, our cases were mostly non-Hispanic white and had insufficient numbers of cases to examine estimates for some racial/ ethnic groups (eg, Asian and Pacific Islander). Last, they may be due to differences in the age range of the comparison populations used [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] ; given the life expectancy for DBMD, inclusion of all male individuals in the comparison population reduced estimates, as evidenced by our extrapolated estimates. 
